[3H] dopamine uptake by platelet storage granules in Parkinson's disease
Related Experiment Video
Updated: Nov 8, 2026

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
Published on: August 11, 2021
J M Rabey1, H Shabtai, E Graff
1Department of Neurology, Sackler Faculty of Medicine, Tel-Aviv University, Israel.
Abstract:
[3H] Dopamine (DA) uptake by platelet storage granules was determined in 10 never-treated patients with Parkinson's disease (PD) (in 6 of them, also after 6 months of levodopa treatment), in 18 long-term levodopa-treated patients and in 15 age-matched normal controls. Maximum velocity (Vmax) of DA uptake was significantly lower in the group of never-treated PD subjects compared to healthy controls (P < 0.001) and also lower compared to the PD long-term treated patients (P < 0.025). The Vmax of PD never-treated changed after submitting the patients to 6 months treatment (P < 0.025) and became similar to the Vmax in the treated group. The apparent Michaelis constant (Km) of DA uptake in PD never-treated was also significantly different from controls (P < 0.005) and also different (but not significantly) from PD "long-term" treated patients. Decreased DA uptake by platelet storage granules in PD may reflect a generalized defect of dopaminergic cells with an impairment in the vesicularization of DA which may contribute to the symptomatology of this motor disease.
More Related Videos
Related Concept Videos
Parkinson Disease ll: Pathophysiology
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease l: Introduction
Parkinson's Disease: Overview
Lysosomal Hydrolases
Neural Regulation

